Clinical relapse · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people in remission or with mildly activeulcerative colitis
1 finding from 1 review
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review
Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Pregabalin may leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (low certainty).
3 findings from 1 review
RR 1.95 [1.4, 2.72]
9 studies · 2663 participants
Low
RR 2.91 [1.92, 4.42]
9 studies · 2663 participants
Very low
RR 1.1 [0.92, 1.31]
9 studies · 2663 participants
Very low
Adverse effects: headache · people with drug‐resistant focal epilepsy
It is very uncertain whether pregabalin changes adverse effect: headache compared with placebo (very low certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in adverse effect: nausea compared with placebo (low certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Pregabalin may leads to higher adverse effect: somnolence compared with placebo (low certainty).
1 finding from 1 review
Weight gain · people with drug‐resistant focal epilepsy
Pregabalin may leads to higher adverse effect: weight gain compared with placebo (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in 50% or greater reduction in seizurefrequency compared with active comparators (low certainty).
3 findings from 1 review
RR 1.03 [0.85, 1.25]
3 studies · 1286 participants
Low
RR 1.6 [1.17, 2.19]
3 studies · 1286 participants
Very low
RR 0.67 [0.62, 0.74]
3 studies · 1286 participants
Moderate
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether pregabalin changes seizure freedom compared with active comparators (very low certainty).
1 finding from 1 review